Details of the Drug Combinations

General Information of This Drug (ID: DMKLAYG)

Drug Name
Altretamine   DMKLAYG
Synonyms
Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine
Indication
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Approved [1]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

401 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
10-hydroxycamptothecin + Altretamine DCQYCPU 10-hydroxycamptothecin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [2]
ABIRATERONE + Altretamine DC6GVW2 ABIRATERONE Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
ABIRATERONE + Altretamine DCIO3D7 ABIRATERONE Chronic myelogenous leukemia (Cell Line: K-562) [3]
ABIRATERONE + Altretamine DCA0EJG ABIRATERONE Renal cell carcinoma (Cell Line: SN12C) [3]
ABIRATERONE + Altretamine DCUHHVN ABIRATERONE Carcinoma (Cell Line: MCF7) [4]
ABIRATERONE + Altretamine DC1BJ6Q ABIRATERONE Invasive ductal carcinoma (Cell Line: BT-549) [4]
ABIRATERONE + Altretamine DCMMR10 ABIRATERONE Adenocarcinoma (Cell Line: SW-620) [2]
ABIRATERONE + Altretamine DCLT3EP ABIRATERONE Amelanotic melanoma (Cell Line: MDA-MB-435) [2]
ABIRATERONE + Altretamine DCLS1J1 ABIRATERONE High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [2]
ABIRATERONE + Altretamine DCAM5NP ABIRATERONE Malignant melanoma (Cell Line: LOX IMVI) [2]
ABIRATERONE + Altretamine DC8VMH9 ABIRATERONE Melanoma (Cell Line: SK-MEL-2) [2]
Altretamine + Pentostatin DC3HHS4 Pentostatin Adenocarcinoma (Cell Line: NCIH23) [3]
Altretamine + Pentostatin DC4NT5O Pentostatin Adenocarcinoma (Cell Line: HCC-2998) [3]
Altretamine + Pentostatin DCTINOY Pentostatin Chronic myelogenous leukemia (Cell Line: K-562) [3]
Altretamine + Cyclophosphamide DCLE51F Cyclophosphamide Adenocarcinoma (Cell Line: SW-620) [3]
Altretamine + Cyclophosphamide DCPUQFC Cyclophosphamide Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Altretamine + Cyclophosphamide DCTANBS Cyclophosphamide Lung adenocarcinoma (Cell Line: HOP-62) [3]
Altretamine + Isoniazid DCHQN4M Isoniazid Adenocarcinoma (Cell Line: A549) [3]
Altretamine + Isoniazid DC0U4DO Isoniazid Adenocarcinoma (Cell Line: HT29) [3]
Altretamine + Isoniazid DCA38RU Isoniazid Adenocarcinoma (Cell Line: SW-620) [3]
Altretamine + Isoniazid DCXJB1U Isoniazid Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Altretamine + Isoniazid DCUEG12 Isoniazid Anaplastic large cell lymphoma (Cell Line: SR) [3]
Altretamine + Isoniazid DCUQVB5 Isoniazid Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Altretamine + Isoniazid DCTY59O Isoniazid Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Altretamine + Isoniazid DC72VBD Isoniazid Glioma (Cell Line: SF-295) [3]
Altretamine + Isoniazid DC4Z9W0 Isoniazid Melanoma (Cell Line: SK-MEL-2) [3]
Altretamine + Ifosfamide DCK9PR4 Ifosfamide Adenocarcinoma (Cell Line: DU-145) [3]
Altretamine + Ifosfamide DC3RJ9E Ifosfamide Adenocarcinoma (Cell Line: NCIH23) [3]
Altretamine + Ifosfamide DCDN6FB Ifosfamide Adenocarcinoma (Cell Line: A549) [3]
Altretamine + Ifosfamide DCJY98F Ifosfamide Adenocarcinoma (Cell Line: HCT116) [3]
Altretamine + Ifosfamide DCJ6SLB Ifosfamide Adenocarcinoma (Cell Line: HT29) [3]
Altretamine + Ifosfamide DCSM6MJ Ifosfamide Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Altretamine + Ifosfamide DCB3QZI Ifosfamide Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Altretamine + Ifosfamide DC0IMNH Ifosfamide Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Altretamine + Ifosfamide DCSKKCS Ifosfamide Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Altretamine + Ifosfamide DC9H68A Ifosfamide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Altretamine + Ifosfamide DCCPQDM Ifosfamide Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Altretamine + Ifosfamide DCPSR4T Ifosfamide Lung adenocarcinoma (Cell Line: EKVX) [3]
Altretamine + Ifosfamide DC8HOFR Ifosfamide Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Altretamine + Ifosfamide DCFOEM2 Ifosfamide Malignant melanoma (Cell Line: LOX IMVI) [3]
Altretamine + Ifosfamide DCW3BMS Ifosfamide Malignant melanoma (Cell Line: UACC62) [3]
Altretamine + Ifosfamide DCUPRSU Ifosfamide Melanoma (Cell Line: UACC-257) [3]
Altretamine + Ifosfamide DCWDGBD Ifosfamide Melanoma (Cell Line: SK-MEL-2) [3]
Altretamine + Ifosfamide DCMYCDX Ifosfamide Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Altretamine + Ifosfamide DCWGI3Z Ifosfamide Renal cell carcinoma (Cell Line: UO-31) [3]
Altretamine + Mitomycin DCREBQH Mitomycin Adenocarcinoma (Cell Line: DU-145) [3]
Altretamine + Mitomycin DCJ841J Mitomycin Adenocarcinoma (Cell Line: A549) [3]
Altretamine + Mitomycin DCFU2WL Mitomycin Astrocytoma (Cell Line: SNB-19) [3]
Altretamine + Mitomycin DCPRV7D Mitomycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Altretamine + Mitomycin DCM67U0 Mitomycin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Altretamine + Mitomycin DC5UENX Mitomycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Altretamine + Mitomycin DCPRSGJ Mitomycin Melanoma (Cell Line: SK-MEL-2) [3]
Altretamine + Mitomycin DCO5FUW Mitomycin Melanoma (Cell Line: UACC-257) [3]
Altretamine + Mitomycin DCKBZIU Mitomycin Renal cell carcinoma (Cell Line: SN12C) [3]
Altretamine + Chlorambucil DCPYE2D Chlorambucil Chronic myelogenous leukemia (Cell Line: K-562) [3]
Altretamine + Chlorambucil DCIXDMB Chlorambucil Lung adenocarcinoma (Cell Line: HOP-62) [3]
Altretamine + ER819762 DCJXSFT ER819762 Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Altretamine + ER819762 DCN6RIP ER819762 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Altretamine + Ifosfamide DCUDCAG Ifosfamide Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Altretamine + Mitomycin DC7KBGK Mitomycin Carcinoma (Cell Line: MCF7) [4]
Altretamine + Mitomycin DCCO0E6 Mitomycin Invasive ductal carcinoma (Cell Line: BT-549) [4]
Altretamine + ER819762 DCJUH1G ER819762 Carcinoma (Cell Line: MCF7) [4]
Aminolevulinic Acid Hydrochloride + Altretamine DCMP1RS Aminolevulinic Acid Hydrochloride High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [2]
Amonafide + Altretamine DC2ZDFT Amonafide Invasive ductal carcinoma (Cell Line: BT-549) [4]
Anastrozole + Altretamine DCCZVGJ Anastrozole Adenocarcinoma (Cell Line: DU-145) [3]
Anastrozole + Altretamine DCGDJY6 Anastrozole Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Anastrozole + Altretamine DCUFJS5 Anastrozole Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Anastrozole + Altretamine DCLF8I1 Anastrozole Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Anastrozole + Altretamine DC253LQ Anastrozole Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Anastrozole + Altretamine DC4XEMF Anastrozole Malignant melanoma (Cell Line: LOX IMVI) [3]
Anastrozole + Altretamine DCW57S5 Anastrozole Melanoma (Cell Line: SK-MEL-2) [3]
Anastrozole + Altretamine DCK4AZR Anastrozole Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Anastrozole + Altretamine DCK2KAG Anastrozole Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Anastrozole + Altretamine DCV3LP9 Anastrozole Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Anastrozole + Altretamine DCVMBWZ Anastrozole Invasive ductal carcinoma (Cell Line: BT-549) [4]
Arfolitixorin + Altretamine DCOGLR8 Arfolitixorin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Arfolitixorin + Altretamine DC5FXUA Arfolitixorin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [2]
Bendamustine hydrochloride + Altretamine DC5PPGG Bendamustine hydrochloride Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Bendamustine hydrochloride + Altretamine DCNY3CI Bendamustine hydrochloride Chronic myelogenous leukemia (Cell Line: K-562) [3]
Bendamustine hydrochloride + Altretamine DCED36L Bendamustine hydrochloride Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Bendamustine hydrochloride + Altretamine DCIV6WD Bendamustine hydrochloride Invasive ductal carcinoma (Cell Line: T-47D) [4]
Bendamustine hydrochloride + Altretamine DCD24S2 Bendamustine hydrochloride Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Bendamustine hydrochloride + Altretamine DCC7TGV Bendamustine hydrochloride Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Bendamustine hydrochloride + Altretamine DC8VQ0A Bendamustine hydrochloride Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Bendamustine hydrochloride + Altretamine DCWGPP4 Bendamustine hydrochloride Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Bendamustine hydrochloride + Altretamine DCM8JHG Bendamustine hydrochloride Melanoma (Cell Line: UACC-257) [2]
Bendamustine hydrochloride + Altretamine DC369TI Bendamustine hydrochloride Melanoma (Cell Line: MALME-3M) [2]
Bendamustine hydrochloride + Altretamine DC38MOU Bendamustine hydrochloride Prostate carcinoma (Cell Line: PC-3) [2]
BIO-300 + Altretamine DC9EGLF BIO-300 Carcinoma (Cell Line: MCF7) [4]
BIO-300 + Altretamine DC0IG6W BIO-300 Invasive ductal carcinoma (Cell Line: BT-549) [4]
BIO-300 + Altretamine DCZLHXP BIO-300 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [2]
Bleomycin + Altretamine DCVDF48 Bleomycin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Busulfan + Altretamine DCVA5OQ Busulfan Adenocarcinoma (Cell Line: DU-145) [3]
Busulfan + Altretamine DCPAAV4 Busulfan Adenocarcinoma (Cell Line: SW-620) [3]
Busulfan + Altretamine DCYTYP2 Busulfan Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Busulfan + Altretamine DCHLKLA Busulfan Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Busulfan + Altretamine DCKU688 Busulfan Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Busulfan + Altretamine DCD0SJ8 Busulfan Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Busulfan + Altretamine DCYLPI8 Busulfan Glioma (Cell Line: SF-295) [3]
Busulfan + Altretamine DC7I0VE Busulfan Lung adenocarcinoma (Cell Line: HOP-62) [3]
Busulfan + Altretamine DCEFUGI Busulfan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Busulfan + Altretamine DCHTONJ Busulfan Renal cell carcinoma (Cell Line: SN12C) [3]
Busulfan + Altretamine DC5THFC Busulfan Carcinoma (Cell Line: RXF 393) [4]
Cabazitaxel + Altretamine DC4VQHH Cabazitaxel Adenocarcinoma (Cell Line: HCT116) [3]
Cabazitaxel + Altretamine DCMXUMT Cabazitaxel Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Cabazitaxel + Altretamine DCFK40D Cabazitaxel Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Cabazitaxel + Altretamine DC41K76 Cabazitaxel Anaplastic large cell lymphoma (Cell Line: SR) [3]
Cabazitaxel + Altretamine DCVYGMK Cabazitaxel Renal cell carcinoma (Cell Line: SN12C) [3]
Cabazitaxel + Altretamine DC1YCGE Cabazitaxel Carcinoma (Cell Line: MCF7) [4]
Cabazitaxel + Altretamine DC97TAG Cabazitaxel Invasive ductal carcinoma (Cell Line: BT-549) [4]
Crizotinib + Altretamine DC8KMQM Crizotinib Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Crizotinib + Altretamine DC6NQLM Crizotinib Renal cell carcinoma (Cell Line: SN12C) [3]
Crizotinib + Altretamine DCSQTGE Crizotinib Carcinoma (Cell Line: RXF 393) [4]
Dacarbazine + Altretamine DCSRCL6 Dacarbazine Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Dacarbazine + Altretamine DC8N2AJ Dacarbazine Glioma (Cell Line: SF-295) [3]
Dacarbazine + Altretamine DCJML8I Dacarbazine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Dacarbazine + Altretamine DCSMQV2 Dacarbazine Colon carcinoma (Cell Line: KM12) [4]
Dactinomycin + Altretamine DC4E6L7 Dactinomycin Adenocarcinoma (Cell Line: HCT-15) [2]
Dasatinib + Altretamine DCMM61S Dasatinib Adenocarcinoma (Cell Line: OVCAR3) [3]
Dasatinib + Altretamine DC8R8VO Dasatinib Adenocarcinoma (Cell Line: SW-620) [3]
Dasatinib + Altretamine DCJBQ03 Dasatinib Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Dasatinib + Altretamine DCD81AO Dasatinib Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Dasatinib + Altretamine DCVF3CU Dasatinib Glioma (Cell Line: SF-295) [3]
Dasatinib + Altretamine DCR799O Dasatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Dasatinib + Altretamine DCEQYNG Dasatinib High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Dasatinib + Altretamine DCKMPLU Dasatinib Lung adenocarcinoma (Cell Line: HOP-62) [3]
Dasatinib + Altretamine DCJIRL0 Dasatinib Melanoma (Cell Line: UACC-257) [3]
Dasatinib + Altretamine DC8OYLH Dasatinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Dexrazoxane + Altretamine DCP2XHG Dexrazoxane Colon carcinoma (Cell Line: KM12) [4]
Dexrazoxane + Altretamine DC1MD7R Dexrazoxane Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Dexrazoxane + Altretamine DC6J5C7 Dexrazoxane High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
DFN-15 + Altretamine DCUOUGJ DFN-15 Amelanotic melanoma (Cell Line: MDA-MB-435) [2]
DFN-15 + Altretamine DC0FP06 DFN-15 High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Docetaxel + Altretamine DCT390J Docetaxel Adenocarcinoma (Cell Line: DU-145) [3]
Docetaxel + Altretamine DCWKW49 Docetaxel Adenocarcinoma (Cell Line: SW-620) [3]
Docetaxel + Altretamine DCO3SYH Docetaxel Anaplastic large cell lymphoma (Cell Line: SR) [3]
Docetaxel + Altretamine DCNNIRS Docetaxel Clear cell renal cell carcinoma (Cell Line: A498) [3]
Docetaxel + Altretamine DCLOKC7 Docetaxel Melanoma (Cell Line: UACC-257) [3]
Epirubicin + Altretamine DCX6A57 Epirubicin Chronic myelogenous leukemia (Cell Line: K-562) [3]
Epirubicin + Altretamine DCODT33 Epirubicin Renal cell carcinoma (Cell Line: UO-31) [3]
Epirubicin + Altretamine DCPIKW2 Epirubicin Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Epirubicin + Altretamine DC1J7IN Epirubicin Amelanotic melanoma (Cell Line: MDA-MB-435) [2]
Estramustine + Altretamine DCR9B85 Estramustine Glioma (Cell Line: SF-295) [3]
Estramustine + Altretamine DC67BLF Estramustine Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Estramustine + Altretamine DCLUQWY Estramustine Lung adenocarcinoma (Cell Line: HOP-62) [2]
Estramustine + Altretamine DCCHNII Estramustine Lung adenocarcinoma (Cell Line: NCI-H522) [2]
Estramustine + Altretamine DC2LB1G Estramustine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
FORMESTANE + Altretamine DC2NBLR FORMESTANE Adenocarcinoma (Cell Line: SW-620) [3]
FORMESTANE + Altretamine DCFD1YP FORMESTANE Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
FORMESTANE + Altretamine DCWNR0M FORMESTANE Glioblastoma (Cell Line: SNB-75) [3]
FORMESTANE + Altretamine DCYEN7C FORMESTANE High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
FORMESTANE + Altretamine DCWO4WK FORMESTANE Malignant melanoma (Cell Line: UACC62) [3]
FORMESTANE + Altretamine DC73DM0 FORMESTANE Melanoma (Cell Line: MALME-3M) [3]
FORMESTANE + Altretamine DC84N2E FORMESTANE Carcinoma (Cell Line: RXF 393) [4]
Fulvestrant + Altretamine DCNS7IB Fulvestrant Glioma (Cell Line: SF-268) [3]
Fulvestrant + Altretamine DCN9JMD Fulvestrant Malignant melanoma (Cell Line: UACC62) [3]
Fulvestrant + Altretamine DCCCW71 Fulvestrant Renal cell carcinoma (Cell Line: UO-31) [3]
Fulvestrant + Altretamine DCHX3SB Fulvestrant Invasive ductal carcinoma (Cell Line: T-47D) [4]
Fulvestrant + Altretamine DCBO9DT Fulvestrant Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Gefitinib + Altretamine DCV3Y69 Gefitinib Adenocarcinoma (Cell Line: HCT116) [3]
Gefitinib + Altretamine DCNRP4I Gefitinib Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Altretamine DCUR09W Gefitinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Hepzato + Altretamine DCZDCNS Hepzato Astrocytoma (Cell Line: SNB-19) [3]
Hepzato + Altretamine DCXJY3D Hepzato Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Hepzato + Altretamine DCI8LHI Hepzato Adenocarcinoma (Cell Line: A549) [2]
Hepzato + Altretamine DCPQW7D Hepzato Adenocarcinoma (Cell Line: HCC-2998) [2]
Hepzato + Altretamine DCDJLK2 Hepzato Amelanotic melanoma (Cell Line: MDA-MB-435) [2]
Hepzato + Altretamine DCM52U7 Hepzato Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Hepzato + Altretamine DCPYLAI Hepzato Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Hepzato + Altretamine DCZ7GRB Hepzato Malignant melanoma (Cell Line: UACC62) [2]
Idarubicin + Altretamine DCQA354 Idarubicin Glioma (Cell Line: SF-539) [3]
Idarubicin + Altretamine DC704PO Idarubicin Renal cell carcinoma (Cell Line: UO-31) [3]
Idarubicin + Altretamine DCWU8UD Idarubicin Adenocarcinoma (Cell Line: NCIH23) [2]
Idarubicin + Altretamine DCQKPE9 Idarubicin Adenocarcinoma (Cell Line: HCC-2998) [2]
Idarubicin + Altretamine DCFNPUY Idarubicin Lung adenocarcinoma (Cell Line: EKVX) [2]
Idarubicin + Altretamine DCOWXNO Idarubicin Lung adenocarcinoma (Cell Line: NCI-H522) [2]
Imatinib + Altretamine DC15OEU Imatinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Imatinib + Altretamine DC6LIM1 Imatinib Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Imatinib + Altretamine DC2QQ95 Imatinib Astrocytoma (Cell Line: U251) [3]
Imatinib + Altretamine DCKWT04 Imatinib Chronic myelogenous leukemia (Cell Line: K-562) [3]
Imatinib + Altretamine DCEFQBB Imatinib Glioblastoma (Cell Line: SNB-75) [3]
Imatinib + Altretamine DCGDMO4 Imatinib Malignant melanoma (Cell Line: UACC62) [3]
Imatinib + Altretamine DCJBEL7 Imatinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Imatinib + Altretamine DCP7WMI Imatinib Prostate carcinoma (Cell Line: PC-3) [3]
Indazole derivative 5 + Altretamine DC7X4TY Indazole derivative 5 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Indazole derivative 5 + Altretamine DCFNHSB Indazole derivative 5 Chronic myelogenous leukemia (Cell Line: K-562) [3]
Indazole derivative 5 + Altretamine DCRWF3X Indazole derivative 5 Renal cell carcinoma (Cell Line: SN12C) [3]
Indazole derivative 5 + Altretamine DCLJNXC Indazole derivative 5 Carcinoma (Cell Line: MCF7) [4]
Indazole derivative 5 + Altretamine DCGX5DQ Indazole derivative 5 Invasive ductal carcinoma (Cell Line: BT-549) [4]
Indazole derivative 5 + Altretamine DCM7E7J Indazole derivative 5 Adenocarcinoma (Cell Line: NCIH23) [2]
Indazole derivative 5 + Altretamine DCFVWCF Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [2]
Indazole derivative 5 + Altretamine DCLLH17 Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Indazole derivative 5 + Altretamine DCGEU84 Indazole derivative 5 Melanoma (Cell Line: SK-MEL-2) [2]
Lapatinib + Altretamine DCW1S71 Lapatinib Carcinoma (Cell Line: RXF 393) [4]
Lapatinib + Altretamine DCYKWZG Lapatinib Astrocytoma (Cell Line: SNB-19) [2]
Lapatinib + Altretamine DCPL6ER Lapatinib Chronic myelogenous leukemia (Cell Line: K-562) [2]
Lapatinib + Altretamine DC6ZUSV Lapatinib High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Lapatinib + Altretamine DCSQFXI Lapatinib Malignant melanoma (Cell Line: UACC62) [2]
Lenalidomide + Altretamine DCYLTM9 Lenalidomide Astrocytoma (Cell Line: SNB-19) [3]
Lenalidomide + Altretamine DCWMR29 Lenalidomide Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Lenalidomide + Altretamine DCL1ZGK Lenalidomide Glioblastoma (Cell Line: SNB-75) [3]
Lenalidomide + Altretamine DC79AWO Lenalidomide Glioma (Cell Line: SF-268) [3]
Lenalidomide + Altretamine DCFYGVN Lenalidomide Invasive ductal carcinoma (Cell Line: T-47D) [4]
Lenalidomide + Altretamine DCITGJX Lenalidomide Adenocarcinoma (Cell Line: DU-145) [2]
Lenalidomide + Altretamine DC8JNY2 Lenalidomide Adenocarcinoma (Cell Line: OVCAR3) [2]
Lenalidomide + Altretamine DCMZFBF Lenalidomide Adenocarcinoma (Cell Line: HCT-15) [2]
Lenalidomide + Altretamine DCJ18JR Lenalidomide Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Lenalidomide + Altretamine DCILU4U Lenalidomide Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Lenalidomide + Altretamine DCN6MTD Lenalidomide Melanoma (Cell Line: SK-MEL-2) [2]
Letrozole + Altretamine DC4HC0B Letrozole Adenocarcinoma (Cell Line: DU-145) [3]
Letrozole + Altretamine DC4J3Z4 Letrozole Adenocarcinoma (Cell Line: NCIH23) [3]
Letrozole + Altretamine DC7T721 Letrozole Glioblastoma (Cell Line: SNB-75) [3]
Letrozole + Altretamine DC2KLHK Letrozole Malignant melanoma (Cell Line: UACC62) [3]
Letrozole + Altretamine DC42FR4 Letrozole Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Letrozole + Altretamine DCWW2I3 Letrozole Invasive ductal carcinoma (Cell Line: T-47D) [4]
LIAROZOLE + Altretamine DCRC3U4 LIAROZOLE Adenocarcinoma (Cell Line: OVCAR3) [2]
LIAROZOLE + Altretamine DCH7E4S LIAROZOLE Adenocarcinoma (Cell Line: HCC-2998) [2]
LIAROZOLE + Altretamine DCNGN19 LIAROZOLE Amelanotic melanoma (Cell Line: MDA-MB-435) [2]
Mechlorethamine + Altretamine DC0XTF6 Mechlorethamine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Mechlorethamine + Altretamine DCHVHE5 Mechlorethamine Anaplastic large cell lymphoma (Cell Line: SR) [3]
Mechlorethamine + Altretamine DCRH7QH Mechlorethamine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Mechlorethamine + Altretamine DCMZGU1 Mechlorethamine Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Mechlorethamine + Altretamine DCY3HUV Mechlorethamine Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Mechlorethamine + Altretamine DCEND2Y Mechlorethamine Carcinoma (Cell Line: RXF 393) [4]
Mechlorethamine + Altretamine DCHOB8Y Mechlorethamine Colon carcinoma (Cell Line: KM12) [4]
Mechlorethamine + Altretamine DC8ZNBG Mechlorethamine Invasive ductal carcinoma (Cell Line: T-47D) [4]
Mechlorethamine + Altretamine DCA8AH8 Mechlorethamine Adenocarcinoma (Cell Line: A549) [2]
Mechlorethamine + Altretamine DC05GKH Mechlorethamine Adenocarcinoma (Cell Line: HCC-2998) [2]
Mechlorethamine + Altretamine DCA06JB Mechlorethamine Adenocarcinoma (Cell Line: HCT-15) [2]
Mechlorethamine + Altretamine DCDIWH7 Mechlorethamine Adenocarcinoma (Cell Line: HT29) [2]
Mechlorethamine + Altretamine DCHWN51 Mechlorethamine Amelanotic melanoma (Cell Line: M14) [2]
Mechlorethamine + Altretamine DCUOG4X Mechlorethamine Amelanotic melanoma (Cell Line: MDA-MB-435) [2]
Mechlorethamine + Altretamine DC1Q378 Mechlorethamine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Mechlorethamine + Altretamine DCJF02T Mechlorethamine Lung adenocarcinoma (Cell Line: HOP-62) [2]
Mechlorethamine + Altretamine DCNHI9W Mechlorethamine Lung adenocarcinoma (Cell Line: MDA-MB-231) [2]
Mechlorethamine + Altretamine DCLPG98 Mechlorethamine Malignant melanoma (Cell Line: LOX IMVI) [2]
Mechlorethamine + Altretamine DCPDMOX Mechlorethamine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Mechlorethamine + Altretamine DCPX06S Mechlorethamine Non-small cell lung carcinoma (Cell Line: HOP-92) [2]
Mechlorethamine + Altretamine DC6M66B Mechlorethamine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [2]
Mepacrine + Altretamine DCX8OZ4 Mepacrine Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Mepacrine + Altretamine DCS3ZM9 Mepacrine Adenocarcinoma (Cell Line: NCIH23) [2]
Mepacrine + Altretamine DC0KVFQ Mepacrine Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Mepacrine + Altretamine DCMGPY8 Mepacrine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Mercaptopurine + Altretamine DCUA7LH Mercaptopurine Lung adenocarcinoma (Cell Line: EKVX) [2]
Methotrexate + Altretamine DCP58AR Methotrexate Melanoma (Cell Line: MALME-3M) [3]
Methotrexate + Altretamine DCM9TBI Methotrexate Invasive ductal carcinoma (Cell Line: T-47D) [4]
Nilotinib + Altretamine DCFGMRR Nilotinib Glioblastoma (Cell Line: SNB-75) [3]
Nilotinib + Altretamine DCXSTAI Nilotinib Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Picoplatin + Altretamine DCK9OW7 Picoplatin Astrocytoma (Cell Line: SNB-19) [3]
Picoplatin + Altretamine DCAWMHB Picoplatin Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Picoplatin + Altretamine DCO7VJ3 Picoplatin Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Picoplatin + Altretamine DCO1OFG Picoplatin Carcinoma (Cell Line: RXF 393) [4]
Picoplatin + Altretamine DC6SBUM Picoplatin Colon carcinoma (Cell Line: KM12) [4]
Picoplatin + Altretamine DCV4OQB Picoplatin Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Picoplatin + Altretamine DC6VC4X Picoplatin Adenocarcinoma (Cell Line: HT29) [2]
Picoplatin + Altretamine DCKH8ME Picoplatin Amelanotic melanoma (Cell Line: M14) [2]
Picoplatin + Altretamine DCVMQB8 Picoplatin Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Picoplatin + Altretamine DC96QT0 Picoplatin Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Picoplatin + Altretamine DCYH84J Picoplatin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Picoplatin + Altretamine DC956K3 Picoplatin Lung adenocarcinoma (Cell Line: MDA-MB-231) [2]
Picoplatin + Altretamine DCP0EUQ Picoplatin Malignant melanoma (Cell Line: UACC62) [2]
Picoplatin + Altretamine DCYXGCE Picoplatin Melanoma (Cell Line: SK-MEL-2) [2]
Picoplatin + Altretamine DC7IGR3 Picoplatin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [2]
Plicamycin + Altretamine DCVY2PO Plicamycin Anaplastic large cell lymphoma (Cell Line: SR) [3]
Plicamycin + Altretamine DC77FHG Plicamycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Plicamycin + Altretamine DCNY327 Plicamycin Renal cell carcinoma (Cell Line: SN12C) [3]
Plicamycin + Altretamine DCQBOUK Plicamycin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Plicamycin + Altretamine DC9QBPB Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [2]
Plicamycin + Altretamine DCPIOP1 Plicamycin Malignant melanoma (Cell Line: LOX IMVI) [2]
PMID28870136-Compound-43 + Altretamine DC7LI19 PMID28870136-Compound-43 Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
PMID28870136-Compound-43 + Altretamine DC2B90M PMID28870136-Compound-43 Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
PMID28870136-Compound-43 + Altretamine DCI9JSL PMID28870136-Compound-43 Glioblastoma (Cell Line: SNB-75) [3]
PMID28870136-Compound-43 + Altretamine DCIGVWE PMID28870136-Compound-43 Invasive ductal carcinoma (Cell Line: HS 578T) [4]
PMID28870136-Compound-43 + Altretamine DCNP4A6 PMID28870136-Compound-43 Adenocarcinoma (Cell Line: HCT116) [2]
PMID28870136-Compound-43 + Altretamine DCMW95C PMID28870136-Compound-43 Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
PMID28870136-Compound-43 + Altretamine DCLVLNS PMID28870136-Compound-43 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
PMID28870136-Compound-43 + Altretamine DC7GC3E PMID28870136-Compound-43 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [2]
PMID28870136-Compound-43 + Altretamine DCOOMVF PMID28870136-Compound-43 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
PMID28870136-Compound-43 + Altretamine DC4J0U5 PMID28870136-Compound-43 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [2]
Pomalidomide + Altretamine DC1UKTS Pomalidomide Adenocarcinoma (Cell Line: OVCAR3) [3]
Pomalidomide + Altretamine DCEK7ZL Pomalidomide Adenocarcinoma (Cell Line: A549) [3]
Pomalidomide + Altretamine DC9BX6L Pomalidomide Adenocarcinoma (Cell Line: HCC-2998) [3]
Pomalidomide + Altretamine DC0TQ62 Pomalidomide Malignant melanoma (Cell Line: LOX IMVI) [3]
Pralatrexate + Altretamine DCIYRQ2 Pralatrexate Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Pralatrexate + Altretamine DCENKQX Pralatrexate Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Pralatrexate + Altretamine DCTSTP9 Pralatrexate Malignant melanoma (Cell Line: UACC62) [2]
Raloxifene + Altretamine DCHN6GP Raloxifene Anaplastic large cell lymphoma (Cell Line: SR) [3]
Raloxifene + Altretamine DCL0S84 Raloxifene Astrocytoma (Cell Line: SNB-19) [3]
Raloxifene + Altretamine DCV83H2 Raloxifene Glioblastoma (Cell Line: SNB-75) [3]
Raloxifene + Altretamine DCWXPEI Raloxifene Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Raloxifene + Altretamine DCNGM0F Raloxifene Carcinoma (Cell Line: RXF 393) [4]
Raloxifene + Altretamine DC6Y397 Raloxifene Colon adenocarcinoma (Cell Line: COLO 205) [4]
Raloxifene + Altretamine DCXFVZT Raloxifene Colon carcinoma (Cell Line: KM12) [4]
Raloxifene + Altretamine DCGZWYZ Raloxifene Adenocarcinoma (Cell Line: HCT116) [2]
Raloxifene + Altretamine DCZO1BB Raloxifene Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Raloxifene + Altretamine DCBRHJW Raloxifene Melanoma (Cell Line: MALME-3M) [2]
Raloxifene + Altretamine DCIJNIS Raloxifene Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Ruxolitinib + Altretamine DCNOVLZ Ruxolitinib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Ruxolitinib + Altretamine DC1MHL3 Ruxolitinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Ruxolitinib + Altretamine DC2JSB1 Ruxolitinib Astrocytoma (Cell Line: SNB-19) [3]
Ruxolitinib + Altretamine DCOW5N2 Ruxolitinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Ruxolitinib + Altretamine DCR3SZ1 Ruxolitinib Chronic myelogenous leukemia (Cell Line: K-562) [3]
Ruxolitinib + Altretamine DCD6CAV Ruxolitinib Glioma (Cell Line: SF-268) [3]
Ruxolitinib + Altretamine DCBYLK1 Ruxolitinib Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Ruxolitinib + Altretamine DC6V8UW Ruxolitinib Renal cell carcinoma (Cell Line: SN12C) [3]
Ruxolitinib + Altretamine DCQIMER Ruxolitinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Ruxolitinib + Altretamine DC2L4XL Ruxolitinib Carcinoma (Cell Line: MCF7) [4]
Ruxolitinib + Altretamine DCS7TW6 Ruxolitinib Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Ruxolitinib + Altretamine DCZ4FBF Ruxolitinib Adenocarcinoma (Cell Line: HCT116) [2]
Ruxolitinib + Altretamine DC9WLA6 Ruxolitinib Adenocarcinoma (Cell Line: HT29) [2]
Ruxolitinib + Altretamine DCE26VT Ruxolitinib Adenocarcinoma (Cell Line: SW-620) [2]
Ruxolitinib + Altretamine DCRKJ26 Ruxolitinib Amelanotic melanoma (Cell Line: MDA-MB-435) [2]
Ruxolitinib + Altretamine DC20J8R Ruxolitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Ruxolitinib + Altretamine DCAOAOK Ruxolitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [2]
Ruxolitinib + Altretamine DCTO64E Ruxolitinib Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Ruxolitinib + Altretamine DCFROKN Ruxolitinib Lung adenocarcinoma (Cell Line: EKVX) [2]
Ruxolitinib + Altretamine DCRTI4G Ruxolitinib Malignant melanoma (Cell Line: LOX IMVI) [2]
Ruxolitinib + Altretamine DCU2QMO Ruxolitinib Melanoma (Cell Line: SK-MEL-2) [2]
SCH 727965 + Altretamine DCHWNMB SCH 727965 Adenocarcinoma (Cell Line: NCIH23) [2]
SCH 727965 + Altretamine DC0UNBB SCH 727965 Amelanotic melanoma (Cell Line: M14) [2]
Sirolimus + Altretamine DCVBZBI Sirolimus Colon adenocarcinoma (Cell Line: COLO 205) [4]
Sirolimus + Altretamine DCXNBUZ Sirolimus Invasive ductal carcinoma (Cell Line: T-47D) [4]
Sirolimus + Altretamine DCQRF6C Sirolimus Adenocarcinoma (Cell Line: HCT116) [2]
Sirolimus + Altretamine DCJ0R2V Sirolimus Prostate carcinoma (Cell Line: PC-3) [2]
Sorafenib + Altretamine DC1ZLS5 Sorafenib Adenocarcinoma (Cell Line: DU-145) [3]
Sorafenib + Altretamine DCQNSWG Sorafenib Adenocarcinoma (Cell Line: HCT116) [3]
Sorafenib + Altretamine DCLLKDX Sorafenib Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Sorafenib + Altretamine DCC493Q Sorafenib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Sorafenib + Altretamine DCT7AO5 Sorafenib High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Sorafenib + Altretamine DC2LD79 Sorafenib Lung adenocarcinoma (Cell Line: EKVX) [3]
Sorafenib + Altretamine DCT3BX2 Sorafenib Melanoma (Cell Line: MALME-3M) [3]
Sorafenib + Altretamine DCR4YCQ Sorafenib Carcinoma (Cell Line: RXF 393) [4]
Sorafenib + Altretamine DCEO53Q Sorafenib Colon carcinoma (Cell Line: KM12) [4]
SY-1425 + Altretamine DC3HT32 SY-1425 Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
SY-1425 + Altretamine DC2M5RT SY-1425 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
SY-1425 + Altretamine DC2BP0F SY-1425 Lung adenocarcinoma (Cell Line: NCI-H522) [2]
SY-1425 + Altretamine DCAKM5M SY-1425 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
TEM + Altretamine DCYE9HA TEM Astrocytoma (Cell Line: SNB-19) [3]
TEM + Altretamine DCD6FV5 TEM Clear cell renal cell carcinoma (Cell Line: A498) [3]
TEM + Altretamine DCN571O TEM Renal cell carcinoma (Cell Line: SN12C) [3]
TEM + Altretamine DCQ9S40 TEM Colon adenocarcinoma (Cell Line: COLO 205) [4]
TEM + Altretamine DCYOYF6 TEM Invasive ductal carcinoma (Cell Line: HS 578T) [4]
TEM + Altretamine DCTFH1A TEM Adenocarcinoma (Cell Line: HCT116) [2]
TEM + Altretamine DC2AWUL TEM High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [2]
TEM + Altretamine DC276NB TEM Malignant melanoma (Cell Line: LOX IMVI) [2]
TEM + Altretamine DC81Q8J TEM Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
TEM + Altretamine DC5EWEH TEM Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [2]
Terameprocol + Altretamine DC10R5C Terameprocol Astrocytoma (Cell Line: U251) [3]
Terameprocol + Altretamine DCVPFDW Terameprocol Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Terameprocol + Altretamine DCGZ6PC Terameprocol Glioma (Cell Line: SF-295) [3]
Terameprocol + Altretamine DC3GD3Z Terameprocol Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Terameprocol + Altretamine DCMGCIZ Terameprocol Colon adenocarcinoma (Cell Line: COLO 205) [4]
Terameprocol + Altretamine DCPGIK7 Terameprocol Colon carcinoma (Cell Line: KM12) [4]
Terameprocol + Altretamine DCSCSH4 Terameprocol Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Terameprocol + Altretamine DC310HB Terameprocol Adenocarcinoma (Cell Line: DU-145) [2]
Terameprocol + Altretamine DC4DR58 Terameprocol Adenocarcinoma (Cell Line: OVCAR3) [2]
Terameprocol + Altretamine DCBBWR5 Terameprocol Adenocarcinoma (Cell Line: A549) [2]
Terameprocol + Altretamine DC8O5AX Terameprocol Adenocarcinoma (Cell Line: HCT116) [2]
Terameprocol + Altretamine DCJ7WYC Terameprocol Melanoma (Cell Line: UACC-257) [2]
Terameprocol + Altretamine DCRWVOO Terameprocol Melanoma (Cell Line: MALME-3M) [2]
Terameprocol + Altretamine DCXJV1N Terameprocol Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Thioguanine + Altretamine DCKREBZ Thioguanine Anaplastic large cell lymphoma (Cell Line: SR) [3]
Thioguanine + Altretamine DCIG9X6 Thioguanine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Topotecan + Altretamine DCIPDNP Topotecan Carcinoma (Cell Line: MCF7) [4]
Topotecan + Altretamine DC0TDQD Topotecan Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Topotecan + Altretamine DCS66Z7 Topotecan Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [2]
Topotecan + Altretamine DCY80MR Topotecan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Triapine + Altretamine DCTMAH8 Triapine Adenocarcinoma (Cell Line: OVCAR3) [2]
Triapine + Altretamine DCK6ZLP Triapine Amelanotic melanoma (Cell Line: M14) [2]
Triapine + Altretamine DC73BQ1 Triapine Glioma (Cell Line: SF-268) [2]
Triapine + Altretamine DCHG6VC Triapine Lung adenocarcinoma (Cell Line: HOP-62) [2]
Triapine + Altretamine DCGIODI Triapine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Uracil mustard + Altretamine DCQNSVR Uracil mustard Invasive ductal carcinoma (Cell Line: BT-549) [4]
Uracil mustard + Altretamine DC5KJX6 Uracil mustard Non-small cell lung carcinoma (Cell Line: HOP-92) [2]
Valrubicin + Altretamine DCBDDQV Valrubicin Clear cell renal cell carcinoma (Cell Line: A498) [3]
Valrubicin + Altretamine DCMLDUA Valrubicin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Valrubicin + Altretamine DCJKJPZ Valrubicin Amelanotic melanoma (Cell Line: MDA-MB-435) [2]
Valrubicin + Altretamine DC6I2AN Valrubicin Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Valrubicin + Altretamine DCQ64WQ Valrubicin Lung adenocarcinoma (Cell Line: EKVX) [2]
Valrubicin + Altretamine DC4OKV4 Valrubicin Lung adenocarcinoma (Cell Line: MDA-MB-231) [2]
Vandetanib + Altretamine DCV6QT3 Vandetanib Carcinoma (Cell Line: MCF7) [4]
Vandetanib + Altretamine DCYLAS0 Vandetanib Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vandetanib + Altretamine DCG8RH2 Vandetanib Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vandetanib + Altretamine DCWDHH1 Vandetanib Adenocarcinoma (Cell Line: SW-620) [2]
Vandetanib + Altretamine DC0TY8H Vandetanib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Vandetanib + Altretamine DC08O50 Vandetanib Amelanotic melanoma (Cell Line: MDA-MB-435) [2]
Vandetanib + Altretamine DCDE4H5 Vandetanib Chronic myelogenous leukemia (Cell Line: K-562) [2]
Vandetanib + Altretamine DC1KE8G Vandetanib Glioma (Cell Line: SF-268) [2]
Vandetanib + Altretamine DCF087Y Vandetanib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Vandetanib + Altretamine DCPIJB1 Vandetanib Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Vandetanib + Altretamine DCTM5G7 Vandetanib Melanoma (Cell Line: SK-MEL-2) [2]
Vandetanib + Altretamine DCFNIAO Vandetanib Renal cell carcinoma (Cell Line: SN12C) [2]
Vemurafenib + Altretamine DC3AZUN Vemurafenib Melanoma (Cell Line: SK-MEL-2) [2]
Vincristine + Altretamine DCBQREG Vincristine Amelanotic melanoma (Cell Line: M14) [3]
Vincristine + Altretamine DCBGQZE Vincristine Astrocytoma (Cell Line: U251) [3]
Vincristine + Altretamine DCZ4W1R Vincristine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Vinflunine + Altretamine DCBBD0A Vinflunine Glioma (Cell Line: SF-539) [3]
Vinflunine + Altretamine DC2PO3G Vinflunine Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vinflunine + Altretamine DCIDHLS Vinflunine Amelanotic melanoma (Cell Line: M14) [2]
Vismodegib + Altretamine DC6EGUC Vismodegib Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Vismodegib + Altretamine DC93X87 Vismodegib Malignant melanoma (Cell Line: LOX IMVI) [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 401 DrugCom(s)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7112).
2 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
3 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.